Drug Database
LA

lamotrigine orally disintegrating tablet (lamotrigine ODT / lamictal ODT / EUR1048)

✓ Approved

Adare Pharma Solutions · SCN1A · 小分子

什么是 lamotrigine orally disintegrating tablet?

lamotrigine orally disintegrating tablet 是一种小分子,由Adare Pharma Solutions研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名lamotrigine ODT, lamictal ODT, EUR1048
公司Adare Pharma Solutions
药物类别小分子
分子靶点SCN1A, SCN2A, SCN3A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

lamotrigine orally disintegrating tablet 作用于 3 个分子靶点:

SCN1Asodium voltage-gated channel alpha subunit 1 (DEE6B, FEB3)
SCN2Asodium voltage-gated channel alpha subunit 2 (Na(v)1.2, BFNIS)
SCN3Asodium voltage-gated channel alpha subunit 3 (Nav1.3, NAC3)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

lamotrigine orally disintegrating tablet 针对 4 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersGeneralised tonic-clonic seizure✓ Approved
Nervous system disordersLennox-Gastaut syndrome✓ Approved
Psychiatric disordersBipolar disorder✓ Approved
Nervous system disordersPartial seizures✓ Approved

相关研究文献

PubMedInternational journal of pharmaceutics2026-08-04

Multimodal convolutional neural network for tablet-level dissolution prediction using compression force and UV fluorescent imaging.

Honti Barbara B, Mészáros Lilla Alexandra LA, Szabó-Szőcs Bence B, Nagy Zsombor Kristóf ZK et al.

The prediction of tablet dissolution from in-process data remains a key challenge in pharmaceutical manufacturing, as in vitro dissolution is a critical quality attribute that cannot be measured inline. In this study, a multimodal convolutional neural network (MI-CNN) was developed to predict tablet-level dissolution profiles for immediate-release tablets, combining images taken under UV illumination and compression force. To evaluate the contribution of input selection and feature representation, the MI-CNN was compared with a single-input CNN (SI-CNN) using images only, and a multilayer perceptron (MLP) based on hand-crafted image descriptors and compression force. All models were evaluated on a dataset generated using a Design of Experiments approach, covering multiple compression forces, disintegrant concentrations, and acetylsalicylic acid particle size fractions. The MI-CNN achieved the most consistent performance, with comparable training and validation errors (RMSE: 13.09% and 12.54%, respectively), and demonstrated robust generalization across formulation conditions, including an unseen particle size range. The SI-CNN showed reduced accuracy (RMSEval: 25.41%), particularly in cases where dissolution differences were governed by tablet compaction. The MLP model exhibited excellent training performance (RMSEtrain: 2.94%) but poor generalization (RMSEval: 27.15%), indicating overfitting due to the limited ability of histogram-based features to adequately represent the complexity of the dataset. Model explanation using SHapley Additive exPlanations (SHAP) revealed that both compression force and image-derived features contributed to the predictions. Overall, the results demonstrate that combining process variables with image-based information enables accurate and robust dissolution prediction at the tablet level, supporting data-driven approaches for real-time release testing.

PMID 42546994
阅读全文 →
PubMedInternational journal of pharmaceutics2026-08-04

Low-temperature FDM 3D printing of immediate-release glipizide tablets: formulation optimization, solid-state characterization, and dose customization.

Thanawuth Kasitpong K, Suttiruengwong Supakij S, Huanbutta Kampanart K, Limmatvapirat Sontaya S et al.

Glipizide (GPZ), a Biopharmaceutics Classification System Class II antidiabetic drug with low aqueous solubility and a high melting point, presents challenges for fused deposition modeling (FDM) 3D printing due to the elevated processing temperatures commonly required. This study investigated low-temperature hot-melt extrusion (HME) and FDM 3D printing for the fabrication of personalized immediate-release GPZ tablets using vinylpyrrolidone-vinyl acetate copolymer (KVA64)-based filaments. GPZ-loaded filaments containing KVA64, mannitol (MAN), and triethyl citrate (TEC) were successfully prepared at 60 °C and printed at 90 °C. Among six formulations investigated, the filament composed of 12% w/w GPZ, 69% w/w KVA64, 10% w/w MAN, and 9% w/w TEC exhibited suitable flexibility, feedability, and moisture resistance. DSC, PXRD, and TGA findings were consistent with a partially amorphous GPZ dispersion containing residual crystalline domains, with no detectable thermal degradation under the processing conditions. A mixed-level factorial design was used to investigate the effects of infill pattern, number of shells, and layer thickness on GPZ release at 10 min. After Bonferroni adjustment for multiple comparisons, infill pattern, number of shells, and the infill pattern × layer thickness interaction remained statistically significant, whereas the main effect of layer thickness did not. Grid infill and fewer shells generally promoted faster drug release, while the effect of layer thickness depended on the infill architecture. Dose-adjusted tablets containing 5, 7.5, 10, and 15 mg GPZ were produced by modifying tablet thickness while maintaining a constant diameter. Thinner tablets exhibited faster dissolution because of their higher surface area-to-volume ratios. However, the 15 mg tablet did not meet the immediate-release dissolution criterion at 30 min, indicating that height-based scaling alone is insufficient for maintaining immediate-release performance at higher doses. These findings demonstrate the potential of low-temperature HME-FDM printing for personalized GPZ tablets while emphasizing the need to optimize both tablet geometry and internal architecture across the intended dose range.

PMID 42546995
阅读全文 →
PubMedForensic toxicology2026-08-04

Identification of 3-chlorophenmetrazine (3-CPM) from new psychoactive substances products and analytical differentiation from the ortho- and para-substituted isomers.

Tanaka Kazue K, Sakamoto Miho M, Ichikawa-Kaji Yoko Y, Saeki Yuki Y et al.

3-Chlorophenmetrazine (3-CPM) is a phenmetrazine analog that has been detected in new psychoactive substance (NPS) products sold on the market. The objective of this study was to perform an analytical characterization of 3-CPM identified in NPS products. In addition, 2-chlorophenmetrazine (2-CPM) and 4-chlorophenmetrazine (4-CPM), which are positional isomers of 3-CPM, were synthesized, and analytical methods for their differentiation were validated to prevent misidentification of the three CPM isomers. Samples were analyzed using liquid chromatography with photodiode array detection (LC/PDA), liquid chromatography-high resolution mass spectrometry (LC/HRMS), gas chromatography-mass spectrometry (GC/MS), gas chromatography-high resolution mass spectrometry (GC/HRMS), nuclear magnetic resonance (NMR) spectroscopy, and X-ray crystallography. Four NPS products sold between October 2022 and February 2023 were found to mainly contain trans-3-CPM, as determined by NMR analysis. Quantitative analysis showed that the powder and crystal products contained approximately 0.86-1.98 g of 3-CPM per package, whereas the tablet product contained approximately 0.10 g of 3-CPM per tablet. In chromatographic analyses, 2-CPM, 3-CPM, and 4-CPM were distinguishable based on retention times using octadecylsilyl silica gel (ODS) and phenyl columns for LC/PDA, and HP-5ms and CycloSil-B columns for GC/MS. Small differences were observed between UV spectra of 2-CPM/3-CPM and that of 4-CPM. Furthermore, 2-CPM produced a characteristic product ion in the LC/HRMS spectrum. The three positional isomers (2-, 3-, and 4-CPM) can be differentiated using LC and GC-based analytical methods. The analytical data presented in this study will facilitate the structural elucidation and accurate identification of novel phenmetrazine analogs in future investigations.

PMID 42550430
阅读全文 →
PubMedDermatologie (Heidelberg, Germany)2026-08-04

[Current and future therapies for bradykinin-mediated angioedema].

Fasshauer Maria M, Dominas Nina N

Bradykinin-mediated angioedema, particularly hereditary angioedema due to C1 esterase inhibitor deficiency or dysfunction (HAE-C1INH), is caused by dysregulation of the kallikrein-kinin system with excessive bradykinin generation and subsequent increased vascular permeability. Modern HAE management is based on three major therapeutic strategies: on-demand treatment, short-term prophylaxis (STP), and long-term prophylaxis (LTP). On-demand treatment options include plasma-derived and recombinant C1 inhibitor (C1INH) concentrates, the bradykinin B2 receptor antagonist icatibant, and, more recently, the first orally available plasma kallikrein inhibitor, sebetralstat. Short-term prophylaxis prior to invasive medical procedures is performed as replacement therapy by intravenous administration of C1INH concentrates. The goal of long-term prophylaxis is complete disease control with reduction of attack frequency and/or severity and improvement of quality of life. LTP therapies include subcutaneous and intravenous C1INH preparations, the oral kallikrein inhibitor berotralstat, the anti-kallikrein monoclonal antibody lanadelumab, the factor XIIa inhibitor garadacimab, and the antisense oligonucleotide donidalorsen. Currently under development are the oral bradykinin B2 receptor antagonist deucrictibant, which is intended for both on-demand treatment and long-term prophylaxis in different formulations, long-acting antibodies, such as navenibart, and CRISPR/Cas9-based gene-editing therapies, such as NTLA-2002 with potential functional curative properties. In particular, orally available and long-acting therapies are expected to improve adherence, self-management, and quality of life in affected patients.

PMID 42550203
阅读全文 →
PubMedJournal of materials chemistry. B2026-08-04

Glucose-derived ultra-small carbon nanozymes for treating inflammatory bowel disease.

Wang Huibo H, Li Hao H, Guo Jiaqing J, Song Jun J et al.

Inflammatory bowel disease (IBD) encompasses a group of common inflammatory intestinal disorders that are currently challenging to cure. Nanozymes, as an emerging class of therapeutics, hold significant promise in treating IBD. In this study, an ultrasmall, metal-free carbon nanozyme (GNZ) was synthesized from glucose through a one-step hydrothermal method. GNZ exhibited quantitatively characterized superoxide dismutase (SOD)-mimicking catalytic activity and broad-spectrum antioxidant capacity against multiple reactive oxygen and nitrogen species. In LPS-stimulated macrophages, GNZ reduced intracellular oxidative stress and the expression of pro-inflammatory markers while promoting an anti-inflammatory macrophage phenotype. Moreover, oral administration of GNZ alleviated disease symptoms, increased colon length, and reduced colonic tissue injury in DSS-induced colitis mice. These findings demonstrate the potential of glucose-derived GNZ as an orally administered antioxidant nanozyme for alleviating intestinal inflammation.

PMID 42549496
阅读全文 →
PubMedInternational journal of pharmaceutics2026-08-04

Predictive compaction modelling of ternary direct compression formulations.

Tait Theo T, Salehian Mohammad M, Aroniada Magdalini M, Shier Andrew P AP et al.

Developing directly-compressed formulations remains a resource-intensive task, requiring substantial experimental effort to characterise the compressibility and compactability of a formulation space. This study extends a global optimisation of mixture rules to a ternary formulation space (API-brittle filler-elastic filler) and investigates the potential for reducing experimental burden whilst maintaining the predictive accuracy of empirical compression and compaction models. Three grades each of paracetamol and ibuprofen, combined with a consistent placebo base, were used to evaluate the approach. The global optimisation outperformed the traditional line of best fit approach, achieving strong predictive performance for the Kawakita model (R2>0.94; RMSE<0.01) and more variable fits for the Ryshkewitch-Duckworth model (R2 = 0.93 - 0.95 and RMSE = 0.23 - 0.39 MPa for paracetamol; R2 = 0.70 - 0.83 and RMSE = 0.31 - 0.37 MPa for ibuprofen). The optimisations performance was found to improve when the training dataset considered only drug-loaded blends. The exploration of reducing experimental burden considered a Model-Based Design of Experiments (MBDoE) which was benchmarked against random experiment selection. Integrating MBDoE with optimised mixture rules reduced API consumption by over 30% across all formulations, with median savings of 75%-95% under Acceptable and Good performance thresholds. Savings decreased with increasing threshold stringency, with the greatest variability observed in ibuprofen formulations. The Kawakita model supported reductions across all threshold levels, whilst the Ryshkewitch-Duckworth model showed limited capacity beyond the Acceptable threshold. tThe MBDoE did not outperform the random selection of experiments, however the optimisation framework for populating empirical compression and compaction models offers a resource-efficient approach to predicting tablet porosity and tensile strength of ternary API loaded blends.

PMID 42546992
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lamotrigine orally disintegrating tablet